Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Serum estrogen receptor bioactivity and breast cancer risk among postmenopausal women.

Lim VW, Li J, Gong Y, Jin A, Yuan JM, Yong EL, Koh WP.

Endocr Relat Cancer. 2014 Feb 27;21(2):263-73. doi: 10.1530/ERC-13-0233. Print 2014 Apr.

2.

Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women.

Fourkala EO, Zaikin A, Burnell M, Gentry-Maharaj A, Ford J, Gunu R, Soromani C, Hasenbrink G, Jacobs I, Dawnay A, Widschwendter M, Lichtenberg-Fraté H, Menon U.

Endocr Relat Cancer. 2012 Apr 10;19(2):137-47. doi: 10.1530/ERC-11-0310. Print 2012 Apr.

3.

Serum free estradiol and estrogen receptor-α mediated activity are related to decreased incident hip fractures in older women.

Lim VW, Li J, Gong Y, Yuan JM, Wu TS, Hammond GL, Jin A, Koh WP, Yong EL.

Bone. 2012 Jun;50(6):1311-6. doi: 10.1016/j.bone.2012.03.006. Epub 2012 Mar 16.

4.

Serum estrogen receptor beta mediated bioactivity correlates with poor outcome in lung cancer patients.

Lim VW, Lim WY, Zhang Z, Li J, Gong Y, Seow A, Yong EL.

Lung Cancer. 2014 Aug;85(2):293-8. doi: 10.1016/j.lungcan.2014.05.019. Epub 2014 Jun 4.

PMID:
24951317
5.
6.

Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers.

Farhat GN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, Huang AJ, Vitolins M, Hubbell FA, Manson JE, Cochrane BB, Lane DS, Lee JS.

J Natl Cancer Inst. 2011 Apr 6;103(7):562-70. doi: 10.1093/jnci/djr031. Epub 2011 Feb 17.

7.

Sex hormone levels and risk of breast cancer with estrogen plus progestin.

Farhat GN, Parimi N, Chlebowski RT, Manson JE, Anderson G, Huang AJ, Vittinghoff E, Lee JS, Lacroix AZ, Cauley JA, Jackson R, Grady D, Lane DS, Phillips L, Simon MS, Cummings SR.

J Natl Cancer Inst. 2013 Oct 2;105(19):1496-503. doi: 10.1093/jnci/djt243. Epub 2013 Sep 16.

8.

A prospective study of endogenous estrogens and breast cancer in postmenopausal women.

Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS.

J Natl Cancer Inst. 1995 Feb 1;87(3):190-7.

PMID:
7707406
9.

Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women.

Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM, Koenig KL, Shore RE, Kim MY, Pasternack BS, Toniolo P.

Am J Epidemiol. 1997 Jun 1;145(11):1030-8.

10.

Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women.

Miyoshi Y, Tanji Y, Taguchi T, Tamaki Y, Noguchi S.

Clin Cancer Res. 2003 Jun;9(6):2229-33.

11.
12.

Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.

Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE.

J Natl Cancer Inst. 2004 Dec 15;96(24):1856-65.

13.

Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy.

Würtz AM, Tjønneland A, Christensen J, Dragsted LO, Aarestrup J, Kyrø C, Overvad K, Olsen A.

Cancer Causes Control. 2012 Oct;23(10):1711-20. doi: 10.1007/s10552-012-0050-7. Epub 2012 Aug 28.

PMID:
22926300
14.

Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study.

Widschwendter M, Lichtenberg-Frate H, Hasenbrink G, Schwarzer S, Dawnay A, Lam A, Menon U, Apostolidou S, Raum E, Stegmaier C, Jacobs IJ, Brenner H.

Br J Cancer. 2009 Jul 7;101(1):160-5. doi: 10.1038/sj.bjc.6605106. Epub 2009 Jun 2.

15.

Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort.

Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, Evangelista A, Allemani C, Micheli A, Tagliabue G, Schunemann HJ, Menard S, Berrino F, Muti P.

Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):169-76. doi: 10.1158/1055-9965.EPI-08-0808.

16.

Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.

Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE.

J Natl Cancer Inst. 2006 Oct 4;98(19):1406-15.

17.

Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).

Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folkerd EJ, Willett WC, Wolmark N, Hankinson SE.

J Natl Cancer Inst. 2006 Jan 18;98(2):110-5.

18.

Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women.

Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2029-35. doi: 10.1158/1055-9965.EPI-08-0262.

19.

Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).

Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, Peeters P, Quirós JR, Roddam A, Thiebaut A, Tjønneland A, Chirlaque MD, Trichopoulou A, Trichopoulos D, Tumino R, Vineis P, Norat T, Ferrari P, Slimani N, Riboli E.

J Natl Cancer Inst. 2005 May 18;97(10):755-65.

20.

Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women.

Adly L, Hill D, Sherman ME, Sturgeon SR, Fears T, Mies C, Ziegler RG, Hoover RN, Schairer C.

Int J Cancer. 2006 Nov 15;119(10):2402-7.

Items per page

Supplemental Content

Write to the Help Desk